Agios Pharma (AGIO) Received its Third Buy in a Row

By Austin Angelo

After Piper Jaffray and Leerink Partners gave Agios Pharma (NASDAQ: AGIO) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Chris Shibutani reiterated a Buy rating on Agios Pharma today. The company’s shares opened today at $56.59.

According to, Shibutani is a 3-star analyst with an average return of 3.4% and a 42.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as G1 Therapeutics Inc, Puma Biotechnology, and Seres Therapeutics.

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $85, which is a 50.2% upside from current levels. In a report issued on February 14, Piper Jaffray also maintained a Buy rating on the stock with a $100 price target.

See today’s analyst top recommended stocks >>

Based on Agios Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $91.79 million. In comparison, last year the company had a GAAP net loss of $88.29 million.

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year. Most recently, in December 2018, Scott Biller, the CSO of AGIO bought 20,500 shares for a total of $47,765.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.